Feature | December 07, 2012

Tryton Completes Patient Enrollment in Pivotal FDA Side Branch Stent Trial

Study Is the first and largest randomized multi-center bifurcation trial

Tryton Side Branch Stent TRYTON Pivotal FDA IDE trial

December 7, 2012 — Tryton Medical Inc. announced the completion of enrollment in the TRYTON Pivotal U.S. Food and Drug Administration (FDA) IDE trial evaluating the Tryton Side Branch Stent.

The landmark TRYTON pivotal study is an international randomized trial that compares a Tryton stent in the side branch vs. conventional provisional stenting (balloon angioplasty) in the side branch, with both arms of the trial utilizing a standard drug eluting stent in the main vessel. The study, which is the first and only randomized IDE pivotal clinical trial to evaluate a dedicated bifurcation stent, has enrolled 704 patients at 67 centers in North America, Europe and Israel. The primary endpoint of the study is target vessel failure at nine months. A secondary endpoint is percent diameter stenosis at nine months in the side branch vessel.

Martin B. Leon, M.D., F.A.C.C., professor of Medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, and founder and chairman emeritus of the Cardiovascular Research Foundation, serves as principal investigator of the study.

“Completion of patient recruitment is a major milestone for the TRYTON IDE Pivotal Trial, which is truly a landmark study. In addition to being the first powered randomized controlled trial evaluating a dedicated side branch stent, it is the largest coronary bifurcation study ever attempted and the first one to have core angiographic (3-D and planar) and IVUS sub-studies. The results of the TRYTON study will directly guide the treatment of patients with complex bifurcation disease,” said Leon. “Our current inability to treat these lesions with ‘work horse’ drug eluting stents, represents an important unmet clinical need which confronts interventional cardiologists. From my travels to Europe and Israel, I have been impressed with how easily the Tryton Stent is incorporated into routine practice. We look forward to results from this trial.”

“Tryton Medical’s differentiated technology addresses the challenges of bifurcated lesions, which affect nearly a third of patients undergoing a PCI procedure. Data from more than 1,000 registry patients in Europe treated with the Tryton stent are already challenging provisional stenting, with compelling results of target lesion revascularization of four percent and thrombosis of 0.5 percent at one year," said Shawn P. McCarthy, president and CEO of Tryton Medical. “We are looking to corroborate this positive registry data in the TRYTON Medical randomized controlled study. With more than 6,000 implants to date, we are leveraging our impressive data to further expand globally. We are on track to be the first and only approved stent for coronary bifurcations in the U.S.”

Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

For more information please visit www.trytonmedical.com

Related Content

News | Cath Lab| October 09, 2015
October 9, 2015 — Cardinal Health is launching its expanded portfolio in the cardiova
Shimadzu, MIX package, Trinias Cardiovascular suites, U.S. availability

Image courtesy of Shimadzu Medical Systems

Technology | Cath Lab| October 08, 2015
Shimadzu Medical Systems USA announced the availability of the MIX package for the Trinias Cardiovascular suites. Based...
ORSIF, radiation exposure for interventionalists, greater on left side of head, Ehtisham Mahmud
Feature | Radiation Dose Management| October 06, 2015
The results of a research study indicate that interventional cardiologists receive “very high” radiation exposure...
Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
Overlay Init